Biden doesn’t get it
By H. Holden Thorp,
Science
| 02. 18. 2022
It has been a rough 2 weeks for the US science community. After 4 years of bludgeoning by the Trump administration, hope resurged a year ago as a new White House promised to value science. But there have been missteps, the most recent taking place on the heels of another blunder that many saw coming. Eric Lander, who just stepped down as President Biden’s science adviser and director of the Office of Science and Technology Policy (OSTP), was a prominent research figure with a well-known record of bullying and callous actions. With the notable exception of the 500 Women Scientists organization, the scientific community was embarrassingly silent about Lander’s nomination. Not surprisingly, he is out of the White House because of the same behavioral issues. And yet, in another tone deaf move, the administration just named Francis Collins, the recently retired director of the National Institutes of Health (NIH), as Lander’s interim replacement as science adviser while asking Alondra Nelson, the OSTP’s deputy director for science and society and an experienced administrator and scholar, to temporarily direct OSTP. Apparently, Biden...
Related Articles
By Jacob M. Apel, The Baltimore Sun | 08.16.2024
By Neha Kondaveeti, The Austin Chronicle | 08.16.2024
It’s been a busy couple of months in biopolitics, with developments in the US, UK, China, Japan, and implicitly on Mars. Time for a brief roundup.
• • •
Bioethics needs an update
The National Research Act is now 50 years old. It was signed into law on July 12, 1974, as a direct response to publicity about the 1932 “Tuskegee Study of Untreated Syphilis in the Negro Male.” The Hastings Bioethics Forum celebrated its anniversary with an...
Image courtesy National Human Genome Research Institute
The U.S. Food and Drug Administration (FDA) is supposed to encourage effective medical advances while also ensuring that patients and research subjects are protected. This dual mandate demands tricky judgment calls that are made more difficult by outside pressures of several kinds, political, judicial, and especially commercial. This April story at Bloomberg examines one deeply troubling pattern of regulatory capture:
Americans Are Paying Billions to Take Drugs That Don’t Work
Companies are increasingly...